Minervax AB
559235-0085ActiveDeveloping a life-saving prophylactic vaccine against Group B Streptococcus.
Biotechnology Companyminervax.com
Yleiskatsaus
- 20–49
- Työntekijät
- 50–100milj SEK
- Liikevaihto
- 2020
- Perustettu
Avainpäättäjät
Per Fischer
CEO
@minervax.com
Bengt Johansson Lindbom
CSO
Christopher Gagliardi
Board member
Tal Zaks
Board member
+22 lisää yhteystietoja Funnelfeedrissä
Kuvaus
MinervaX is a clinical-stage biotechnology company dedicated to making a significant global impact through medical innovation. The organization focuses specifically on developing a state-of-the-art prophylactic vaccine targeting Group B Streptococcus (GBS). Their primary motivation is to prevent adv...